Brave new world: The current and future use of novel anticoagulants
- 1 December 2008
- journal article
- review article
- Published by Elsevier in Thrombosis Research
- Vol. 123, S29-S35
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee ArthroplastyNew England Journal of Medicine, 2008
- Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory studyJournal of Thrombosis and Haemostasis, 2007
- The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacementJournal of Thrombosis and Haemostasis, 2007
- Extended Prophylaxis of Venous Thromboembolism with IdraparinuxNew England Journal of Medicine, 2007
- Idraparinux versus Standard Therapy for Venous Thromboembolic DiseaseNew England Journal of Medicine, 2007
- Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939)Circulation, 2007
- Investigational treatments of venous thromboembolismExpert Opinion on Investigational Drugs, 2007
- Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacementJournal of Thrombosis and Haemostasis, 2005
- BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging studyJournal of Thrombosis and Haemostasis, 2005
- Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factorJournal of Internal Medicine, 2003